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lpers-Huttenlocher syndrome is an uncommonmitochondrial diseasemost often associated
ith mutations in the mitochondrial DNA replicase, polymerase-g. Alterations in enzyme
activity result in reduced levels or deletions inmitochondrial DNA. Phenotypicmanifestations
occurwhen the functional content ofmitochondrial DNA reaches a critical nadir. The tempo of
disease progression and onset varies among patients, even in identical genotypes. The classic
clinical triad of seizures, liver degeneration, and progressive developmental regression helps
deﬁne the disorder, but awide range of clinical expression occurs. Themajority of patients are
healthy before disease onset, and seizures herald the disorder in most patients. Seizures can
rapidly progress to medical intractability, with frequent episodes of epilepsia partialis con-
tinua or status epilepticus. Liver involvement may precede or occur after seizure onset.
Regardless, eventual liver failure is common. Both the tempo of disease progression and range
of organ involvement vary from patient to patient, and are only partly explained by patho-
genic effects of genetic mutations. Diagnosis involves the constellation of organ involvement,
not the sequence of signs. This disorder is relentlessly progressive and ultimately fatal.
 2013 Elsevier Inc. All rights reserved.Introduction
Bernard Alpers is credited with the inﬂuential descrip-
tion of a 4-month-old girl with normal development who
developed intractable seizures in the context of a 1-month
illness [1]. Although this disease was likely described
much earlier [2], the description by Alpers led to the
recognition and fostered further reports of this disorder.
Forty-ﬁve years later, Huttenlocher et al. [3] described the
associated hepatic features and cerebrospinal ﬂuid ﬁnd-
ings, and conﬁrmed earlier suggestions of autosomal
recessive inheritance [4]. More than 25 years passed until
the seminal symptomatic description by Harding [5] of 32
patients with a distinctive liver and brain pathology,Dr. Saneto; Division of
al; 4800 Sand Point Way
ll rights reserved.deﬁning the typical clinical course of the disease. Harding
described normal early development, an insidious onset of
developmental delay, failure to gain weight (thrive), bouts
of vomiting, and pronounced hypotonia. Seizure onset
occurred during these early manifestations, but in some
children, seizures heralded the disease. After seizure onset
occurred, the clinical course became rapidly progressive.
Liver involvement was variable in onset. In some patients
it preceded seizure onset, and in others it only occurred
during the terminal stages of the disease [6]. Postmortem
liver examination demonstrated a characteristic combina-
tion of ﬁndings (Table 1) [7]. Examination of the cerebral
cortex revealed variability but a constant involvement of
the calcarine cortex with microscopic changes, including
spongiosis, neuronal loss, and astrocytosis, which pro-
gressed down through the cortical layers.
The cloning and characterization of the gene poly-
merase-g by Ropp and Copeland [8] ushered in the
molecular era of polymerase-g-related disorders, and in
Table 1. Speciﬁc histologic ﬁndings of the liver in Alpers-Huttenlocher
syndrome [7]
At least three of these features must be present (Wilson disease has
been excluded):
1. Bridging ﬁbrosis or cirrhosis
2. Bile ductular proliferation
3. Collapse of liver cell plates
4. Hepatocyte dropout or focal necrosis, with or without portal inﬂammation
5. Microvesicular steatosis
6. Oncocytic change (mitochondrial proliferation associated with intensely
eosinophilic cytoplasm in scattered hepatocytes and not affect by steatosis)
7. Regenerative nodules
8. Parenchymal disease or disorganization of the normal lobular architecture
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polymerase-g-induced disorders helped deﬁne a category
of mitochondria-nuclear communication disorders, i.e.,
diseases of mitochondrial DNA maintenance. The bio-
chemical and enzymatic relevance of polymerase-g to
Alpers-Huttenlocher syndrome was established by Naviaux
et al. with their description of mitochondrial DNA depletion
and reduced polymerase-g enzyme activity [9]. In 2001, the
ﬁrst patients were reported with pathogenic mutations in
polymerase-g, presenting with progressive external oph-
thalmoplegia and “progressive external ophthalmoplegia
plus” syndromes [10]. The Alpers-Huttenlocher syndrome
genotype-to-phenotype link was established in 2004, when
Naviaux and Nguyen [11] described mutations in poly-
merase-g responsible for the clinical entity of Alpers-
Huttenlocher syndrome. These data completed the full
pathophysiology of the clinical phenotype, the identiﬁca-
tion of a genetic etiology, and the physiologic changes of
reduced mitochondrial DNA content inducing the mito-
chondrial DNA depletion syndrome of Alpers-Huttenlocher
syndrome. Within the next 3 years, an outline of the full
spectrum and clinical descriptions of polymerase-g disor-
ders was nearly completed, with both dominant and
recessive mutations known to cause a wide spectrum of
clinical disease [12].
Clinical features of Alpers-Huttenlocher syndrome
Range of polymerase-g diseases
There are more than 180 mutations and counting in
polymerase-g-producing mitochondrial diseases that vary
in age at onset, mode of inheritance, and expression of
clinical features [12-22]. Most of the dominant mutations
cause illnesses with onset in the later adult years, and
these mutations reside in the catalytic residues of the
polymerase domain of polymerase-g [23]. Illness caused
by recessive mutations is observed throughout the life-
span and represents the predominant disease inheritance
pattern in polymerase-g diseases [14,15]. Disease-causing
mutations occur throughout all exons in polymerase-g,
and produce many clinical syndromes as well as multiple
organ system diseases that do not cluster within distinct
phenotypic syndromes [12-14,24] (http://niehs.niehs.nih.
gov/polg/). Although more than a dozen common muta-
tions are known, many patients with autosomal recessive
disease manifest compound heterozygote mutations, with
a nearly unlimited number of possible combinations given
the 180 identiﬁed pathogenic mutations.Infant and childhood onset polymerase-g diseases
The clinical expression of myocerebrohepatopathy is
distinct from that of Alpers-Huttenlocher syndrome [12,14].
Myocerebrohepatopathy is much less common than Alpers-
Huttenlocher syndrome. Its onset usually occurs by 6
months of age, i.e., much earlier than Alpers-Huttenlocher
syndrome. These infants usually present with liver failure
and lactic acidosis, and then may develop encephalopathy,
not necessarily involving seizures. The liver involvement in
myocerebrohepatopathy is often the most devastating
feature, without the hepatic pathology observed in Alpers-
Huttenlocher syndrome (Table 1) [7]. Alpers-Huttenlocher
syndrome and myocerebrohepatopathy are therefore
sometimes confused with each other because of the rapid
progression leading to early death [1,5,9,12]. The clues to
distinguish these polymerase-g entities from one another
include the presence of medically intractable seizures,
associated devastating encephalopathy, and if patients live
long enough, a distinctive, pathologically deﬁned liver
involvement in Alpers-Huttenlocher syndrome [5,11].
However, liver involvement may occur early and to variable
extents in the course of the Alpers-Huttenlocher syndrome
[5], making the distinction difﬁcult in some cases.
Alpers-Huttenlocher syndrome
The hallmark clinical features of Alpers-Huttenlocher
syndrome include intractable seizures, developmental
regression, and liver dysfunction. This triad of clinical
hepatocerebral features and seizures, when combined with
two of 11 other ﬁndings, constitutes the clinical diagnosis of
Alpers-Huttenlocher syndrome (Table 2).
Onsetmost commonly occurs between ages 2 and 4 years
(range, 3 months to 8 years) [5,20,25]. The age at onset of
Alpers-Huttenlocher syndrome is bimodal, with a second
peak onset between ages 17 and 24 years, with a range of
ages 10-27 years [26-28]. Infants and children with Alpers-
Huttenlocher syndrome are healthy until disease onset,
although some investigators have identiﬁed nonspeciﬁc
developmental delays. Age at onset is inﬂuenced, in part, by
speciﬁc mutations within the polymerase-g gene, other
genes [29], and environmental factors such as intercurrent
viral infections andcertainmedications suchasvalproic acid.
Changes within the polymerase-g nucleotide sequence can
induce changes in the enzyme activity of polymerase-g that
are inﬂuenced by the environment. These changes in
enzyme activity are called ecogenetic structural nucleotide
variant changes, and they can alter the age at onset, severity
of disease, and organ involvement of Alpers-Huttenlocher
syndrome [12,14]. The environmental inﬂuence of concur-
rent viral illness can also induce the onset of Alpers-
Huttenlocher syndrome and the stepwise progression of
this disorder. The full set of mechanisms for this variability
remains uncertain.
Harding [5,28] described the later age at onset, and this
second peak for the onset of Alpers-Huttenlocher syndrome
hasbeenconﬁrmedbyother reportsdescribingpolymerase-g
mutations in this population [21,26,27]. The age range of this
older group of patients with Alpers-Huttenlocher syndrome
comprises 17-24 years. As will be further described, the
majority of patients in the group with older ages at onset
Table 2. Diagnostic criteria for Alpers-Huttenlocher syndrome [7]
1. Clinical triad of refractory seizures, psychomotor regression, and hepatopathy
2. In the absence of hepatopathy (Table 1) or additional ﬁndings, the diagnosis can only be conﬁrmed by polymerase-gamma gene sequencing, liver biopsy, or
postmortem examination
3. Additional clinical ﬁndings (at least two of the 11 ﬁndings must be present):
a. Cranial proton magnetic resonance spectroscopy indicating reduced N-acetyl aspartate, normal creatine, and elevated lactate
b. Elevated cerebrospinal ﬂuid protein (>100 mg/dL)
c. Cerebral volume loss (central more than cortical, with ventriculomegaly) on repeated magnetic resonance imaging or computed tomography
d. At least one electroencephalogram revealing multifocal paroxysmal activity with high-amplitude d slowing (200-1000 mV) and spikes/polyspikes
(10-100 mV, 12-25 Hz)
e. Cortical blindness or optic atrophy
f. Abnormal visual-evoked potentials and normal electroretinogram ﬁndings
g. Quantitative mitochondrial DNA depletion in skeletal muscle or liver (35% of the mean)
h. Deﬁciency in polymerase-g enzymatic activity (10%) in skeletal muscle or liver
i. Elevated blood or cerebrospinal ﬂuid lactate (3 mM) on at least one occasion in the absence of acute liver failure
j. Isolated complex IV or a combination of complex I, III, and IV electron transport defects (20% of normal) upon liver respiratory chain testing
k. A sibling conﬁrmed as manifesting Alpers-Huttenlocher syndrome
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merase-g, homozygous p.A467T, or p.W748S transitions in
the linker region. An attractive hypothesis contends that the
later age range of onset is attributable to homozygous
mutations in the linker region. However, a compound
heterozygous p.T851A and p.R1047Wwas recently reported
[26]. Thus, the location of mutations is, in part, responsible
for alterations in polymerase-g activity and phenotype,
althoughothermodifying factors are also clearly responsible.
Organ involvement
Organs involved in Alpers-Huttenlocher syndrome pri-
marily include those that require large amounts of energy
and that are prone to oxidative damage, which include the
brain, peripheral nervous system, liver, and gastrointestinal
tract.
Nervous system involvement
Seizures comprise the most dramatic central nervous
feature of Alpers-Huttenlocher syndrome. In about 50% of
patients, seizures constitute the heralding sign. After
seizures appear, the tempo of the disease becomes rapidly
progressive. Death usually occurs within 4 years of onset
[26-28]. In other cases, disease progression is slower [14,21].
The etiology for the variation in disease progression remains
unknown. Theﬁrst associationof valproic acidwith the rapid
onset of liver disease in a child with Alpers-Huttenlocher
syndrome was reported in 1992 [30], and soon led to the
understanding that the clinical variables associated with
valproate-induced liver failure were in fact the clinical
features of Alpers-Huttenlocher syndrome. Therefore, val-
proic acid (and divalproex sodium) have likely altered the
natural history of Alpers-Huttenlocher syndrome and may
have given the impression of a universal, rapidly progressive
disease. Because we can rapidly identify patients with
Alpers-Huttenlocher syndrome and because we have
established that valproate is contraindicated in this disorder,
an analysis of seizure frequency, duration, and medication
use (without exposure to valproic acid) needs to be per-
formed to understand the natural history of disease
progression without this variable.
Electroencephalogramﬁndings andseizure semiologycan
vary from patient to patient, and change as the disease
progresses in any patient. Some patients manifest febrileconvulsions, whichmay indicate comorbid seizure networks
in some patients [31]. Often, the initial afebrile seizure
semiologyandelectroencephalogramarenotwell-described.
However, in those patients with well documented electro-
encephalogram studies and witnessed seizures, occipital
lobeﬁndings aremost common. Focal, asymmetric, occipital-
predominant seizures present as visual and tactile halluci-
nations, nausea and vomiting, dysautonomia, headache and
eye nystagmus auras, or seizures, often together with focal
or generalized motor seizures [31,32]. The electroence-
phalogram, during the initial period of seizure manifesta-
tions, often exhibits occipital-predominant epileptiform
discharges, with the concomitant focal slowing of frequency
(Fig 1). Epileptiform wave morphologies are described as
spikes/polyspikes, andmay be unilateral or bilateral over the
posterior head region [31-34]. As the disease progresses,
most patients manifest repeated episodes of status epi-
lepticus and epilepsia partialis continua [9,11,20,21,31,35-37].
Over time, seizures become more resistant to medical
therapy, and individual seizures demonstrate longer dura-
tions. Myoclonus and myoclonic seizures become more
prominent and almost continuous, and both are refractory to
medical treatment. Death is not unusual in the setting of
persistent seizures and myoclonus. In any patient with
epileptic encephalopathy without adequate explanation,
Alpers-Huttenlocher syndrome should be considered and
valproate should be avoided unless genetic testing for poly-
merase-g produces normal results, because for unclear
reasons, valproic acid induces liverdysfunction that results in
liver failure [11,30,31,38,39]. Seizures and the lack of effective
medical control comprise major morbidities, with death
commonly attributable to uncontrolled seizures.
The predominance of neuronal loss in the calcarine and
striate cortices presents clinically as blindness. Visual loss
may be transitory early in the course of Alpers-Huttenlocher
syndrome, but usually becomes permanent at some point
during disease progression. Microscopic changes involve
spongiosis, neuronal loss, and astrocytosis, which extend
and progress into the depth of the cortex [5]. Early in the
disease, central volume loss exceeds cortical volume loss and
can lead to the appearance of hydrocephalus ex vacuo [9]. In
the terminal phases of the disease, the entire cortexbecomes
a thin gliotic scar, with resultant cerebral atrophy. These
pathologic changes likely correlate with the evolving
encephalopathy as the disease progresses. Medically
Figure 1. Electroencephalogram segment from a 7-year-old girl with Alpers-Huttenlocher syndrome. Regional slowing in the parieto-occipital regions is
demonstrated bilaterally, with epileptiform discharges within the right occipital region. The scale represents time (1-second intervals) and amplitude
(microvolts).
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cerebellum is variably involved, often with Purkinje cell
dropout and Bergman gliosis with a preserved granular cell
layer [11]. The degree of ataxia likely relates to the loss of
Purkinje cells.
Most patients are healthy initially, but some can de-
monstrate nonspeciﬁc neurologic features, such as clumsi-
ness, migraine headaches, progressive ataxia, or mild
medically controlled seizures before explosive seizure onset
[21,26,31,35]. Migraine headaches can be associated with
visual hallucination auras because of the occipital lobe
involvement [21,35].
Other nervous system manifestations are reported
in Alpers-Huttenlocher syndrome. The predominance of
neuronal cell loss in the calcarine and striate cortices induces
cortical blindness. Visual loss may be initially transitory, but
as the disease progresses, may become complete. Cranial
nerve dysfunction with abnormal eye movements and the
delayed acquisition of smooth pursuits (i.e., the delayed
maturation of cranial nerves and eye movement networks
within the cortex and cerebellum) are attributable to central
andperipheralneuronaldysfunction. Theperipheralnervous
system is also involved in most patients with disease
progression.
Evaluating sensory neuropathy in young children is
difﬁcult, and it often escapes identiﬁcation until muscle
stretch reﬂexes are lost. The objective losses of pain and
temperature perceptions, vibratory sensation, and lighttouch sensation usually comprise late ﬁndings. In older
patients with recessive polymerase-g mutations, sensory
peripheral neuropathy was demonstrated to be attributable
to a loss of the peripheral axonal branches of the dorsal root
ganglia neurons, secondary to neuronal death [40]. The
same mechanism likely occurs in younger children, but
rigorous testing in the younger population with Alpers-
Huttenlocher syndrome has not been reported. However,
sensory neuropathy has been reported as an early ﬁnding in
younger patients [31]. Ataxia can comprise an early feature
and is universally observed during the course of the disease
because of cerebellar, sensory nerve ascending pathway, or
cortical tract involvement [31,34,36,41].
Liver involvement
Environmental exposures canaccelerate liverdysfunction.
Exposure to valproic acid inducing severe liver dysfunction
hasbeenadeﬁning featureofAlpers-Huttenlocher syndrome
[11,30-32,39]. Liver dysfunction occurs without exposure to
valproate, and is part of the deﬁning natural history of this
illness. According to the early description of the disease by
Huttenlocher et al. [3] and later descriptions by Harding
[5,28], liver involvement without exposure to valproic acid
has comprised one of the deﬁning features. Furthermore, the
histochemical changes induced by valproic acid are identical
to those observed without exposure (Table 1) [5,7]. The
pathologic features of Alpers-Huttenlocher syndrome are
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or toxic liver disorders [42,43]. Like other organ involve-
ments, the expression of liver dysfunction varies between
patients. However, exposure to valproic acid seems the
catalyst for liver dysfunction, regardless of the patient’s
inherited predisposition or early or late liver involvement.
Unfortunately, the exact mechanism of liver alterations
remains elusive. Almost all patients who live long enough
will eventually develop liver involvement and subsequent
failure.
In the situation where the patient receives valproic acid,
liver dysfunction usually beginswithin 2-3months, butmay
be delayed by up to 6 months. Liver dysfunction is usually
heralded by hypoglycemia, decreased albumin synthesis,
the reduced synthesis of coagulation factors, and mild
transaminase elevations. The early recognition of liver
dysfunction may halt the progression to failure. One study
demonstrated that the use of intravenous levocarnitine
reversed the course of early valproic acid-induced hepatic
failure [44]. In rare cases, liver dysfunction induced by
valproic acid can be reversed by drug withdrawal [32,45].
Hypoglycemia, as in several other electron transport
chain disorders, can constitute an early sign of Alpers-
Huttenlocher syndrome, especially during liver immaturity
during the ﬁrst 1-2 years of age [46]. Onset in the ﬁrst year of
agewith normal liver biopsy results has been described [31].
Slightly older patients have been described with fasting
hypoglycemia [47]. Inexplicably, the hypoglycemic events
may resolve over time. The precise etiology remains unclear,
but likely reﬂects a secondary impairment of mitochondrial
fatty acid oxidation because of electron transport chain
dysfunction. Coagulopathies may occur with or without
frank cirrhosis in Alpers-Huttenlocher syndrome. These
result from the hepatic biosynthetic failure of vitamin K-
dependent clotting factors II, VII, IX, and X. However, in the
intensive care unit, prothrombotic episodes of deep venous
(e.g., subclavian or femoral) thrombosis at the site of venous
line placement are commonly observed in patients with
Alpers-Huttenlocher syndrome. This thrombosis can be
caused by a relative deﬁciency in the liver synthesis of
anticoagulant proteins C and S or anti-thrombin III.
Gastrointestinal involvement
Many patients develop swallowing dysfunction, delayed
gastric emptying, and intestinal dysmotility, which all
worsen as the disease progresses. These children often
require the placement of a gastric tube for nutrition in the
midstage of the disorder. The use of continuous gastric tube
feedings is often required because normal bolus feedings are
not tolerated due to poor gastric and intestinal motility.
Disease progression often results in complete gastrointes-
tinal dysmotility, and many patients require jejunal tube
feedings and eventually total parenteral nutrition. A
complete loss of the longitudinal muscularis propria
external muscle layer in the gastrointestinal tract was
evident in twopatientswith Alpers-Huttenlocher syndrome
at autopsy, ﬁrst presenting at ages 2 and 13 years (R.P.
Saneto, unpublished data). Mitochondrial DNA depletion
within themuscularis propriawas demonstrated in an infant
who died at age 20 days with polymerase-g mutations
compatible with Alpers-Huttenlocher syndrome [48]. Asimilar pathologic ﬁnding was reported in another mito-
chondrial DNA depletion syndrome, mitochondrial neuro-
gastrointenstinal encephalomyopathy disease [49]. The
reason for the speciﬁc nature of the loss of the external
muscle layer of the gastrointestinal tact remains unknown,
but the mitochondrial DNA depletion within the smooth
muscle of the muscularis propria of both diseases may be
responsible.
Pancreatitis may also occur in Alpers-Huttenlocher
syndrome. To invoke pancreatitis as a result of valproic acid
exposure is tempting, especially because the valproic acid
induction of pancreatitis is a well-known side effect in
patients with epilepsy [50]. However, Harding [5] described
pancreatitis in patients not exposed to valproic acid. The
mechanismofpancreatitis inAlpers-Huttenlocher syndrome
remains unknown.
Cardiac involvement
Cardiomyopathy and congestive failure occur in perhaps
10%of childrenwithAlpers-Huttenlocher syndrome.Although
not common, this complication can further compromise liver
functionwhen signiﬁcant right-sided failure is present.
Diagnosis of Alpers-Huttenlocher syndrome
Genetic testing
Sequencing polymerase-g should be performed if Alpers-
Huttenlocher syndrome is suspected. Although screening for
the few most common mutations may capture most cases,
most experts nowrecommend full sequencing.More than60
mutations inpolymerase-g are reported tobeassociatedwith
Alpers-Huttenlocher syndrome, so the number and combi-
nation of mutations make full sequencing of the gene the
most sensitive and speciﬁc method in conﬁrming a diag-
nosis. The use of gene sequencing demonstrates more
importance in Alpers-Huttenlocher syndrome than in other
biochemical disorders because no speciﬁc or sensitive
biochemical markers are available for polymerase-g disease.
Some evidence exist that 3-methylglutaconic aciduria and
electron transport chain involvement may entail more
severely affected disease [51]. Muscle tissue may exhibit
a mosaic histochemical staining pattern in cells negative for
cytochrome C oxidase and enhanced trichrome staining
(ragged red ﬁbers). However, neither of these ﬁndings is
diagnostic for Alpers-Huttenlocher syndrome.
Electron transport chain enzymology
The depression of electron transport chain enzymatic
activities in muscle and liver is not speciﬁc for Alpers-
Huttenlocher syndrome and constitutes an insensitive
method of diagnosis, especially during the early course of
the illness. Reports demonstrated a variable pattern of
electron transport chain defects, ranging from completely
normal to single and multiple electron transport chain
deﬁciencies [24,38]. The variability of electron transport
chain complex activity ﬁndings is likely related to the stage
of disease and the tissue tested. As the disease progresses,
abnormal electron transport chain activities become more
pronounced as the catalytic subunits of the various
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activity. Therefore, analyses of electron transport chain
should not be used to screen for or diagnose Alpers-
Huttenlocher syndrome.
Mitochondrial DNA content
The mitochondrial DNA copy number in patients with
Alpers-Huttenlocher syndrome comprises 3-40% of normal
[11,18,22]. The use of mitochondrial DNA content may
seem useful for diagnosis, but it is not sensitive or speciﬁc
for Alpers-Huttenlocher syndrome because mitochondrial
DNA content may be normal early in the disease. In addi-
tion, mitochondrial DNA depletion may be observed in
other diseases with muscle and liver involvement, making
diagnoses based on mitochondrial DNA content misleading
(Table 3). Muscle and liver mitochondrial DNA depletion
may lag behind other disease features. Some mutations
alter the ﬁdelity of the transcript and not the mitochon-
drial DNA content, rendering the mitochondrial DNA
useless. In such cases, the mitochondrial DNA content will
be normal [52]. If mitochondrial DNA content is measured,
only liver and muscle tissue should be used, because
polymerase-g mutations do not always induce mitochon-
drial DNA depletion in blood cells [53]. As the disease
progresses, almost all patients with Alpers-Huttenlocher
syndrome will begin to demonstrate mitochondrial DNA
depletion. Rare exceptions have been reported in patients
with Alpers-Huttenlocher syndrome who demonstrated
mitochondrial DNA deletions without mitochondrial DNA
depletion [54]. Therefore, the ﬁnding of mitochondrial
DNA depletion may be helpful in a diagnosis, but its
absence cannot be used to exclude Alpers-Huttenlocher
syndrome.Table 3. Disorders of mitochondrial maintenance (mitochondrial DNA depletion dis
Gene Age on Onset CNS Features
POLG1 Infancy to adult Ataxia, seizures, dementia, blindness,
DGUOK Neonatal Dystonia, nystagmus, hypotonia
MPV17 Neonatal to adult Ataxia, neuropathy, dystonia, hypoton
TWINKLE Infancy Athetosis, seizures, myopathy, MR, PE
neuropathy, ataxia, hypotonia
TK2 Infancy to childhood Seizures, PEO
RRM2B Neonatal Microcephaly, MR, hearing loss, hypot
SUCLG1 Neonatal Hypotonia, severe early encephalopath
SUCLA2 Neonatal to infancy Dystonia, hearing loss, encephalopath
neuropathy, MR, hypotonia
Abbreviations:
CNS ¼ Central nervous system
DGUOK ¼ Deoxyguanosine kinase
GI ¼ Gastrointestinal
MPV17 ¼ Encodes a small mitochondrial membrane protein of unclear function
MR ¼ Mental retardation
PEO ¼ Progressive external ophthalmoplegia
POLG1 ¼ Polymerase-g1
RRM2B ¼ p53-dependent ribonucleotide reductase
SUCLG1 ¼ Guanosine triphosphate-dependent succinyl-coenzyme A synthase
SUCLA2 ¼ Adenosine triphosphate-dependent succinyl-coenzyme A synthase
TK2 ¼ Thymidine kinase
TWINKLE ¼ Mitochondrial DNA helicase
* Liver failure is induced by exposure to valproic acid, but will also occur without expos
traits. Autosomal dominant forms of polymerase-g syndromes are only found in adult onElectroencephalogram ﬁndings and seizures
Well-described and speciﬁc electroencephalogram ﬁnd-
ings and seizure semiology early in the disease course may
suggest Alpers-Huttenlocher syndrome as a diagnosis (Fig
1). Explosive seizures with an asymmetric occipital-lobe
predominance of epileptiform discharges that evolve into
status epilepticus or epilepsia partialis continua, combined
with psychomotor delay, occur frequently in Alpers-
Huttenlocher syndrome and not in other illnesses, so these
ﬁndings should signal the possibility of Alpers-Huttenlocher
syndrome [31-33]. Only a few epileptic syndromes,
including early-onset childhood epilepsy with occipital
spikes (Panayiotopoulos syndrome), late-onset childhood
epilepsy with occipital spikes (Gastaut type), Lafora disease,
celiac disease, the syndrome of mitochondrial encephalo-
myopathy, lactic acidosis, and stroke-like episodes, myoc-
lonus and epilepsy with ragged red ﬁbers, epilepsy with
bilateral occipital calciﬁcations, idiopathic photosensitive
occipital epilepsy, and malformations of cortical develop-
ment, demonstrate a posterior head predominance of spike/
polyspike and wave epileptiform discharges [55]. This
combination of epileptiform location and seizure semiology
should also signal the clinician to conﬁrm that polymerase-g
is normal before initiating valproic acid.
Neuroimaging
Neuroimaging ﬁndings are nonspeciﬁc, but can be helpful
in diagnoses. Computed tomography andmagnetic resonance
imagingmay produce normal results early in the course of the
disease, but as the disease progresses, magnetic resonance
imaging changes reﬂect acute and chronic pathologic changes.
Diffusion-weighted imaging acquisition is most sensitive fororders)
Systemic Features Depletion Organs
PEO, neuropathy Liver failure,* GI dysmotility,
vomiting, myopathy
Liver, muscle
Liver failure Liver
ia Liver failure, MR, scoliosis,
corneal scarring
Liver
O, psychosis, Liver failure Liver
Myopathy Muscle
onia Myopathy, tubulopathy,
nephrocalcinosis
Muscle, kidney
y Lactic acidosis, hepatomegaly Liver, muscle
y, PEO, Muscle
ure. Mitochondrial DNA depletion syndromes are inherited as recessive or dominant
set disorders.
R.P. Saneto et al. / Pediatric Neurology 48 (2013) 167e178 173demonstrating early Alpers-Huttenlocher syndrome lesions
that cannot be detected by routine magnetic resonance
imaging [39]. The occipital location of electroencephalogram
abnormalities and neuronal loss/gliosis can sometimes be
observed on magnetic resonance imaging as hyperintensities
on T2/ﬂuid attenuated inversion recovery sequences in the
occipital regions, suggesting mitochondrial dysfunction [55].
Often when seizures are uncontrolled, T2/ﬂuid attenuated
inversion recovery hyperintensities are prominent in the
thalami and basal ganglia [32]. A transient resolution of
magnetic resonance changes may also occur, with normali-
zation of the signal changes [56]. However, as the disease
progresses, magnetic resonance imaging demonstrates
atrophy, reﬂecting the pathologic changes in the basal ganglia
and brainstem induced by the disease [5,54]. Some patients
manifest cerebellar involvement, which corresponds to the
prominent Purkinje cell loss observed in autopsies [5].
The diagnosis of Alpers-Huttenlocher syndrome requires
a great deal of clinical acumen. The clinical expression of
signs and features varies in timing, intensity, and severity.
Clinical suspicion is necessary early in the course of diag-
nosis, because the sequence of signs may be distinctive for
each patient. However, the constellation of clinical signs
will eventually be expressed, and polymerase-g sequencing
will conﬁrm the diagnosis.
Genetics of Alpers-Huttenlocher syndrome
Polymerase-g protein
The polymerase-g protein constitutes the only known
DNA polymerase in the mammalian mitochondria, and isFigure 2. Functional and structural domains of the polymerase protein. (A) Line
region comprises the mitochondrial targeting sequence, and is located at the
evident between the exonuclease and linker region, as well as within the polyme
III for its activity. The polymerase domain contains subdomains comprising the T
Two regions comprise the Palm subdomain within the polymerase domain. Th
activity [23,57]. Arrows indicate the numbered positions of amino acids that
polymerase holoenzyme [59]. The color scheme of the polymerase-g catalytic s
blue for the exonuclease region, red for the accessory interacting domain (AID) d
motifs in the exonuclease (I, II, and III) and in the polymerase (A, B, and C) a
proximal subunit, and grey for the distal subunit.responsible for mitochondrial DNA replication and repair
[23,57]. Polymerase-g is encoded by the polymerase-g gene
on chromosome 15q25, synthesized in cytoplasm, and
transported to its inner mitochondrial matrix. Here in the
inner membrane it associates with other nuclear encoded
proteins that comprise themtDNA replisome and nucleoids.
Polymerase-g demonstrates three distinct DNA activities:
a 50->30 DNA polymerase, a 30->50 exonuclease, and 50-
deoxyribose phosphate lyase. The exonuclease activity is
located within the N-terminal region, and is connected by
a linker region to the C-terminal domain, which contains the
50-30 polymerase activity (Fig 2A). The polymerase region
contains three subdomains named Palm, Fingers, and
Thumb. The C-terminal domain contains 50-30-polymerase
activity and 50-deoxyribose phosphate lyase activity. The
exact location of 50-deoxyribose phosphate lyase activity
within the C-terminal region remains unknown [58]. Three
highly conserved sequence motifs within the exonuclease
region (I, II, and III) and three within the polymerase region
(A, B, and C) are essential for full polymerase-g activity
[23,57]. Within the linker region are two regions required
for full activity, the accessory protein interacting domain
located toward the N-terminal part of the linker region, and
the intrinsic processivity subdomain located distally in the
linker region (toward the C-terminal).
Holoenzyme
The holoenzyme of polymerase-g is a heterotrimer
containing one molecule of polymerase-g associated with
two molecules of polymerase-g2 [8,59]. Polymerase-g2, the
55-kDa accessory protein, enhances the processivity (thear organization of the polymerase-g protein. The N-terminal domain (NTD)
N-terminal of the protein. The Thumb subdomains (Th) of the protein are
rase region [63]. The exonuclease domain contains essential motifs I, II, and
humb (Th), Palm, and Finger, which contain motifs A, B, and C, respectively.
e motifs located within the polymerase domain are critical for polymerase
begin a subdomain. (B) Three-dimensional structure of the human DNA
ubunit is the same as in A, i.e., light blue for the polymerase domain, dark
omain, and orange for the intrinsic processivity (IP) domain. The conserved
re charcoal-colored. The two accessory subunits are colored green for the
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association-disassociation with the template DNA) of the
holoenzyme [60]. One site of polymerase-g2 association
involves the linker region at the accessory protein inter-
acting domain of the catalytic subunit (Fig 2B) [61]. This
interaction increases the DNA-binding afﬁnity of the holo-
enzyme. The second polymerase-g2 protein makes limited
contact with polymerase-g and is labeled the distal acces-
sory site (Fig 2B) [60]. The interaction of polymerase-g2
with this distal site enhances the polymerization rate of the
holoenzyme [61]. The replisome complex also comprises
the mitochondrial DNA helicase PEO1 (Twinkle), a single-
stranded DNA binding protein, mitochondrial single
stranded deoxyribonucleic acid-binding protein, and
a number of accessory proteins and transcription factors
[23].
Polymerase-g genetics
Alpers-Huttenlocher syndrome comprises an autosomal
recessive disorder. Both copies of polymerase-g are expressed
in mammalian cells, and the monoallelic expression of
wild-type polymerase-g is sufﬁcient to avoid disease [62].
Homozygote-dominant polymerase-g mutations (or even
a dominant polymerase-g mutation with a recessive muta-
tion) have not been described, suggesting that these possible
mutation combinations are likely embryonic lethal. Although
the mutations producing Alpers-Huttenlocher syndrome are
distributed along the entire length of the polymerase-g gene,
mutations tend to cluster within distinct tertiary regions in
the gene [63]. Thus far, no dominant mutations have been
reported to cause Alpers-Huttenlocher syndrome. Autosomal
dominantmutations inpolymerase-g areonlyknownto cause
progressive external ophthalmoloplegia, and occur primarily
in the polymerase region. Recessive mutations within the
polymerase region decrease polymerase activity, alter DNA-
binding afﬁnity, and lower catalytic efﬁciency [63]. Muta-
tions in the linker region of the accessory protein interacting
domain mediate interactions with polymerase-g2 and
destabilize the polymerase-g-DNA complex. When muta-
tions are detected in the intrinsic processivity region, they
induce decreases in processivity, DNA binding, and poly-
merase activity [64]. Mutations within the exonuclease
region, speciﬁcally in the Finger subdomain, confer parti-
tioning of the DNA substrate between the polymerase and
exonuclease sites, and predict a diminution of polymerase
ﬁdelity [63]. However, mutations in the exonuclease region
did not diminish exonuclease activity, but rather conferred
their effects on polymerase activity [65,66].
Recessive mutations in polymerase-g can be present as
homozygous or compound heterozygous mutations. In
general, in trans compound heterozygous mutations induce
a more severe phenotype, whereas homozygous recessive
mutations are associatedwithmilder and later-onset disease
[23,39]. Both types of recessive mutations are associated
with early childhood and juvenile-onset Alpers-Hutten-
locher syndrome. However, for reasons not yet understood,
either in trans compound heterozygous or homozygous
mutations can be observed in the severe early-onset
phenotype and in milder juvenile-onset Alpers-Hutten-
locher syndrome. The reasons for such disparate genotype/
phenotype variations within a single syndrome, i.e., Alpers-Huttenlocher syndrome, and the larger group of poly-
merase-g syndromes remain incompletely understood.
A partial explanation for the phenotypic variability
within Alpers-Huttenlocher syndrome may involve the
location of themutationwithin the gene. In trans compound
heterozygote mutations are usually associated with more
severe early-onset or childhood disease. The combination of
mutations within two distinct regions of polymerase-g cau-
ses a compoundingof the reduction in enzymeactivity,more
severely compromising mitochondrial DNA replication [63].
The most common examples comprise patients with the in
trans compound heterozygote mutation within the linker
region and polymerase region, p.A467T/p.W748S, which is
expressed in terms of decreased survival and an increased
incidence of liver failure, compared with patients with the
homozygous mutations p.A467T/p.A467T and p.W748S/
p.W748S [13,21,67]. Unfortunately, this attractive hypoth-
esis cannot fully explain why these same homozygous
mutations can also give rise to early-onset Alpers-Hutten-
locher syndrome, or why the same in trans compound
heterozygote mutations can give rise to other distinct poly-
merase-g syndromeswith awide range of disease onsets and
severity [17,21]. Thus, although combinations of mutations
within distinct regions of polymerase-g are likely, in part, to
determine the phenotype of Alpers-Huttenlocher
syndrome, other unknown mechanisms are also involved.
Ecogenetic structural nucleotide variants
One potential emerging mechanism for phenotypic vari-
ability involves the ﬁnding of silent nucleotide poly-
morphisms, i.e., ecogenetic structural nucleotide variants
that (depending on environmental or epigenetic situations)
can alter disease expression. When present, a particular
polymerase-g genotype would remain silent unless speciﬁc
conditions are present that can either lead to disease or
modify phenotype. The polymorphic nature of polymerase-g
suggests that ecogenetic structural nucleotide variants may
exist [14]. Two of these ecogenetic structural nucleotide
variants have emerged. Within the Northern European
population, p.E1143G and p.Q1236H have been described
[20,67,68]. The variant p.E1143G exhibits a frequency of
approximately 4.5%, and p.Q1236H exhibits a frequency of
approximately 8.6% in the Northern European population,
but these variants are almost nonexistent in Asian, Sub-
Saharan African, and African-American populations (http://
ww.ncb/htm.nih.gov/SNP_ref.cgi?rs¼23-7441). The pres-
ence of the ecogenetic structural nucleotide variant
p.E1134G has been demonstrated to increase the catalytic
rate for incoming nucleotides and to increase intrinsic
stability, according to in vitro studies [64]. When present in
cis with certain pathologic mutations, especially with the
p.W748S mutation, p.E1143G can modify the disease
phenotype by enhancing enzyme activity [20,67]. This same
ecogenetic structural nucleotide variant can also increase
the liver’s sensitivity to valproic acid [68]. Thus, the ecoge-
netic structural nucleotide variant p.E1143G can modify
disease by either enhancing enzyme activity or compro-
mising liver function, dependingon thegenetic situation and
environmental exposures. Aswith p.E1143G, the presence of
p.Q1236H can induce liver sensitivity to valproic acid. The
presence of either p.E1143G or p.Q1236H is estimated to
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question arises ofwhether eitherof the ecogenetic structural
nucleotide variants is wholly or partly responsible for the
liver failure induced by exposure to valproic acid in Alpers-
Huttenlocher syndrome. According to preliminary
evidence, both p.E1143G and p.Q1236H are likely indepen-
dent fromother, yet unknown, polymerase-gmutations that
induce liver failure. Six previous patients with Alpers-
Huttenlocher syndrome and liver failure did not manifest
either ecogenetic structural nucleotide variant [31] (L.-J.C.
Wong, personal communication). Rare reports have
described the long-termuse of valproic acid in the context of
polymerase-gmutations without liver failure [21]. Whether
other valproic acid-sensitive ecogenetic structural nucleo-
tide variants exist remains unclear, as does a full under-
standing of valproic acid-induced liver failure.
Other ecogenetic structural nucleotide variants, such as
the p.R964C mutation, induce high levels of lactic acidosis
via mitochondrial toxicity when polymerase-g is exposed to
the nucleoside reverse-transcription inhibitor, stavudine
[69]. This ecogenetic structural nucleotide variant was
demonstrated to manifest a similar binding afﬁnity for
thymidine triphosphate as a wild-type enzyme, and only
a 33% decrease in thymidine triphosphate incorporation
efﬁciency. However, the p.R964C mutation induced a three-
fold decrease in the discrimination of 20,30-didehydro-30-
deoxy-thymidine-50-triphosphate incorporation over the
natural substrate (thymidine triphosphate) in addition to
impaired polymerase function, suggesting this decrease acts
as a mechanism of stavudine (d4T)-induced mitochondrial
toxicity [70]. Whether other ecogenetic structural nucleo-
tide variants exist that may alter polymerase-g function and
clinical features remains unclear, but this mechanism of
altering enzyme activity may be important in deﬁning
environmental alterations in clinic phenotype.
Other genes causing Alpers-Huttenlocher syndrome
Alterations in other genes that comprise part of
the mitochondrial DNA replisome can induce Alpers-
Huttenlocher syndrome. Two siblings have been described
with in trans compound heterozygote mutations in the
mitochondrial DNA helicase PEO1 (Twinkle) [29]. The
autopsy of one of the siblings who died during a status epi-
lepticus event revealed that the liver changes did not meet
the strict criteria of histochemical and structural ﬁndings in
Alpers-Huttenlocher syndrome (Table 1). However, the
young age at death of this patient likely prevented the full
expression of liver changes, because the other features of
Alpers-Huttenlocher syndrome were present (Table 1).
Epidemiology of polymerase-g mutations in Alpers-
Huttenlocher syndrome
The true prevalence of Alpers-Huttenlocher syndrome
remains unknown. Because of its high mortality and early
death, the epidemiologic parameters of its incidence
and prevalence are not informative. However, Alpers-
Huttenlocher syndrome must be uncommon for several
reasons. The minimum birth frequency of children who will
developmitochondrial disease is estimatedat approximately
1 in 5000 [71]. Of this population, up to 25% will developpolymerase-g disease [19]. Crude estimates from published
reports suggest that up to 30% of patients with recessive
polymerase-g mutations manifest Alpers-Huttenlocher
syndrome. However, the true ﬁgures remain unknown. A
best estimate for the birth prevalence of children who will
ultimately develop Alpers-Huttenlocher syndrome involves
about 1 in 100,000 [72]. Clearly, more reliable population
studies are required for better estimates of the incidence and
prevalence of Alpers-Huttenlocher syndrome.
Population estimates of common mutations
The most common mutation to induce Alpers-
Huttenlocher syndrome and associated polymerase-g spec-
trum disorders is reportedly p.A467T. The second most
common mutation in Alpers-Huttenlocher syndrome and
polymerase-g spectrum disorders is p.W748S. Elegant pop-
ulation studies demonstrated that bothmutationsarose from
a common ancestor within various populations of Northern
European decent [73]. The carrier frequency of p.A467T is
estimated to be as high as 0.6% in Belgium and 1% in Norway,
and the frequency of p.W748S estimated at 1:125 in Finland
[35,36,73]. Other founder gene mutations for Alpers-
Huttenlocher syndrome have not been discovered in other
ethnic populations. Whether a founder effect is exclusive to
theNorthern European ethnic population remains unknown,
because most of the early mutational research centered on
North European populations. Polymerase-g mutations
inducing Alpers-Huttenlocher syndrome have been detected
in many other ethnic groups [31,74,75]. As more patients
are described with polymerase-gmutations, more “hot spot”
regions of polymerase may be uncovered.
Sex
Males and females seem equally affected in Alpers-
Huttenlocher syndrome [12,14,21,38]. A nonsigniﬁcant
slight increase in males in the infant age group and a mild
female predominance in the older age range were observed
in Alpers-Huttenlocher syndrome.
Therapy
Treatment of manifestations
Treatment is limited to symptom management, and
supportive care and familyeducation should be addressed as
soon as the family is able to absorb the diagnosis. The global
perspective of care should be palliative, even if death is not
imminent. Quality-of-life issues, and speciﬁcally the inten-
sity of treatment that can be offered when major changes
occur in disease status, will be the subject of critical
conversations. This illness progresses to fatal encephalop-
athy or liver failure, and varying levels of treatment are
available and can be addressed openly with the family.
Supportive carewill include the placement of a gastrostomy
feeding tube for medication, hydration, or nutrition.
Different levels of supportive ventilation may include less
invasive treatments such as continuous positive airway
pressure or bilevel positive airway pressure-assisted nasal
ventilation, or may involve the placement of a tracheostomy
and the use of mechanical ventilation. The involvement of
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discussions, and in practical aspects of implementation.
Most patients use rehabilitative services, and rehabilitation
units are oftenwhere family members learn to care for their
loved ones with gastrostomy tubes and ventilatory support.
Occupational, physical, or speech therapy is performed to
maintain neurologic function for as long as possible, and to
ensure comfort when deterioration begins.
Consultation with a gastroenterologist early in the
disease course is necessary to address feeding and nutri-
tional issues, and to assess and manage liver pathology. The
surgical placement of a gastric feeding tube when appro-
priate can maintain nutritional status and prevent aspira-
tion during oral feedings, but in some situations, given the
ultimate course of the illness, some families may notwish to
take this course.
Ventilation disorders are common in Alpers-Huttenlocher
syndrome, and can exist long before hypoventilation is clin-
ically obvious. The assessment of both daytime and nocturnal
ventilatory function can be performed for evidence of central
or obstructive apnea using polysomnography via the
measurement of carbon dioxide partial pressure and by
monitoring via pulse oximetry. Tracheostomy placement and
artiﬁcial ventilation may be performed, but again, some
familiesmaywish to allow the natural course of the illness to
proceed without this invasive and usually lifelong approach.
Attempts should be undertaken to control seizures as
much as possible. However, refractory epilepsy (especially
epilepsia partialis continua) may be impossible to control
with any treatment, and the side effects of treatment may
outweigh anyclinical beneﬁts. Noevidence exists that newer
medications such as lamotrigine, topiramate, oxcarbazepine,
or levetiracetam offer better therapeutic advantages over
the older medications (phenobarbital, phenytoin, carba-
mazepine, andprimidone). However, the newermedications
tend to be less sedative, may require less processing by the
liver, and may involve fewer drug-drug interactions. Val-
proic acid (divalproex sodium) should be avoided. Because
other anticonvulsants have also been implicated in acceler-
ating liver deterioration, it is reasonable to monitor liver
functions every 2-4 weeks after introducing any new
medications.
Movement disorders are common and some, such as
chorea and athetosis, may cause pain. Muscle relaxants and
pain medications, including narcotics, would be advised
under these circumstances. Some movement disorders can
be treated with dopaminergic medications such as
levodopa-carbidopa or tetrabenazine, and therefore a trial
of either of these medications can be considered.
The standard treatment for liver failure can include
small, frequent meals or continuous feeding to compensate
for impaired gluconeogenesis. In addition, reducing dietary
protein to a minimum, the use of nonabsorbable sugars to
create an osmotic diarrhea, and the use of conjugating
agents to treat hyperammonemia may be helpful. Because
levocarnitine may produce some beneﬁts in the setting of
liver failure and because of its low toxicity, some recom-
mend its use from the time of diagnosis.
Liver transplantation in the treatment of liver failure in
Alpers-Huttenlocher syndrome is contraindicated. The
multisystem organ involvement, with relentless progres-
sion in the context of neurocognitive impairment, wouldexclude the isolated correction of liver failure with
transplantation.
Recent reports suggest that cerebrospinal ﬂuid folate
deﬁciency can occur in Alpers-Huttenlocher syndrome [76].
Testing for cerebral folate deﬁciency requires a lumbar
puncture for the detection of 5-methyl-tetrahydrofolate
concentrations in cerebrospinal ﬂuid. Cerebral folate deﬁ-
ciency would be treated with calcium leucovorin, which
crosses the blood-brain barrier and increases cerebral folate
levels. From a practical standpoint, cerebral folate deﬁciency
can occur at any point in the disease process, and because
monitoring cerebrospinal ﬂuid folate a few times per year is
impractical, the use of empiric treatments is reasonable.
No standard-of-care guidelines are available to suggest
the frequency at which these tests should be performed.
Testing should be guided by clinical features, and the
proposed schedule should be modiﬁed if the clinical course
proves stable. Monitoring blood counts, electrolytes, liver
enzymes (aspartate aminotransferase, alanine aminotrans-
ferase, and gamma-glutamyl transpeptidase), and liver
function (by means of preprandial serum glucose concen-
trations, serum concentrations of ammonia, albumin, free
and conjugated bilirubin, and cholesterol, with prothrombin
time or international normalized ratio as measures of
coagulation factors) is reasonable every few months. No
clear evidence indicates that either lactic acid or plasma
amino acids assist in management, but some clinicians ﬁnd
value in these tests. Because of liver disease, monitoring the
plasma concentration of free and total carnitine is reason-
able, even in those who receive levocarnitine supplemen-
tation. Other periodic tests may include liver ultrasound,
electroencephalograms, brainstem auditory evoked poten-
tials, swallowing evaluations, and polysomnography with
pulmonary function tests.Conclusion
Alpers-Huttenlocher syndrome constitutes a mitochon-
drial disorder induced by autosomal recessive mutations in
polymerase-g that decrease mitochondrial DNA replication.
Ultimately, polymerase-g dysfunction induces a progressive
depletion of mitochondrial DNA and evolving organ
dysfunction. Premature death is universal, and often occurs
within 4 years of the onset of features. Alpers-Huttenlocher
syndrome is exclusively an autosomal recessive disorder
caused by homozygous or in trans compound heterozygous
mutations in polymerase-g. No precise phenotype-to-
genotype correlation has been established, although the
location of mutations within speciﬁc regions of polymerase-
g may play a role in the phenotypic expression of the
disorder. Clinically, most patients demonstrate normal early
development, with a timing of onset and progression of
disease that vary in presentation, severity, tempo of
progression, and sequence of organ involvement. However,
the constellation of progressive clinical features within the
brain, liver, and muscle tissue remains the hallmark of the
disease. Many questions remain regarding the elucidation of
mutations or ecogenetic structural nucleotide variants that
alter disease phenotype, the breadth of external factors that
can modify the disease course, and the natural history of
various combinations of mutations (phenotype/genotype).
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Alpers-Huttenlocher syndrome a challenging disease to
treat, and make it emotionally wrenching for families. No
treatments modify the course of the illness, and supportive
treatment is recommended. A novel treatment medication
on the clinical trial pathway may offer hope [77]. Some
exciting ﬁndings in a murine model of polymerase-g disease
were recently reported, suggesting that, if diagnosed early
enough, exercise may signiﬁcantly delay disease manifes-
tations [78]. Whether exercise can help modify the disease
remains to be tested in humans, but the concept is exciting.
Since themolecular, clinical, and biochemical elucidation
of Alpers-Huttenlocher syndrome more than a decade ago,
an enlarging body of information has described the genetic
and environmental elements of Alpers-Huttenlocher
syndrome. Much work must be performed to understand
how genotype inﬂuences phenotype, the discovery of
rational treatments, and better care for patients and fami-
lies. Hopefully, through research and astute clinical judg-
ment, these facets of Alpers-Huttenlocher syndromewill be
clariﬁed.
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